"If all goes well, Heartbeat Health will be a household name for the first referral from primary care for cardiology. It'll be easier than everyone else out there and less expensive than other referrals." Dr. Jeff Wessler, CEO and Founder of Heartbeat Health, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. Dr. Wessler joins BI analyst Jonathan Palmer to discuss the genesis of Heartbeat's decentralized cardiology practice, how the company iterated from a brick and mortar clinic to a virtual platform to speed access, and why keeping patient care at the center has improved outcomes.

See omnystudio.com/listener for privacy information.

Generate Biomedicines’ proprietary platform aims to use generative biology to upend traditional drug development across therapeutic protein modalities. Gevorg Grigoryan, chief technology officer, and Alex Snyder, chief medical officer, sit down with BI analysts Andrew Galler and Sam Fazeli to discuss the general state of AI in drug development and the unique capabilities of the Generate platform in developing novel biologics.

See omnystudio.com/listener for privacy information.

AVS aims to redefine intravascular lithotripsy with its Pulse IVL System, which utilizes hydraulics technology to fracture calcified lesions and expand the diseased vessel with a single device, executive chair Mark Toland explains to Bloomberg Intelligence. In this Vanguards of Health Care episode, Toland sits down with BI analyst Matt Henriksson to discuss what differentiates the Pulse IVL System from current technology to make it more flexible and durable. He also highlights first-in-human results, the next clinical milestones and the mounting market opportunity as an older demographic brings hardened lesions that require IVL technology.

See omnystudio.com/listener for privacy information.